Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan Cardiac Safety Study in Healthy Subjects
NCT03465436Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Fridericia-Corrected QT Interval at 24 hours. Started Sep 2011; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03465436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465436.